When Cure SMA first started funding research thirty years ago, we had to build up from virtually nothing. It’s no easy task. Drug development relies on volume to be successful—just one or two options are not enough. The vast...

When Cure SMA first started funding research thirty years ago, we had to build up from virtually nothing. It’s no easy task. Drug development relies on volume to be successful—just one or two options are not enough. The vast...